Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
Public ClinicalTrials.gov record NCT04616196. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 Monotherapy or in Combination With Cetuximab as a Salvage Regimen for Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC) and colorectal carcinoma (CRC).
Study identification
- NCT ID
- NCT04616196
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 25 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 29, 2020
- Primary completion
- Mar 29, 2023
- Completion
- Mar 29, 2023
- Last update posted
- Jun 7, 2025
2020 – 2023
United States locations
- U.S. sites
- 6
- U.S. states
- 3
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Diego | San Diego | California | 92103 | — |
| University of California, San Francisco | San Francisco | California | 94158 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| START Center for Cancer Care | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Colorectal Cancer trials
Other public records listing Colorectal Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT07796334: Colon Health Champion Program Not yet recruiting
- NCT07071961: Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] Recruiting
- NCT07781852: Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer Not yet recruiting
- NCT07781774: Improving Colorectal Cancer Screening Uptake Through Education and Stool-Based Testing Outreach Not yet recruiting
- NCT07759921: Novel Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer Not yet recruiting
- NCT07738939: IKS04 Regimen in Advanced Solid Tumors That Express CA242 Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04616196, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 7, 2025 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04616196 live on ClinicalTrials.gov.